Free Trial
Alec Stranahan

Alec Stranahan Analyst Performance

Biotechnology Equity Research at Bank of America

Alec Stranahan is a stock analyst at Bank of America, covering 7 publicly traded companies across a range of sectors. Over the past year, Alec Stranahan has issued 9 stock ratings, including buy, hold, and sell recommendations. While full access to Alec Stranahan's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Alec Stranahan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 0 Years
Buy Recommendations
33.33% 3 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy33.3%3 ratings
Hold44.4%4 ratings
Sell22.2%2 ratings

Out of 9 total stock ratings issued by Alec Stranahan at Bank of America, the majority (44.4%) have been Hold recommendations, followed by 33.3% Buy and 22.2% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Alec Stranahan, an analyst at Bank of America, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Alec Stranahan of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
85.7%
MED - DRUGS
1 company
14.3%

Alec Stranahan's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
9/3/2025Downgrade$5.86$7.00Neutral
Xencor, Inc. stock logo
XNCR
Xencor
9/3/2025Downgrade$8.55$12.00Neutral
Erasca, Inc. stock logo
ERAS
Erasca
9/3/2025Reiterated Rating$1.60$1.00Underperform
Novavax, Inc. stock logo
NVAX
Novavax
8/20/2025Reiterated Rating$9.52$7.00Underperform
Novavax, Inc. stock logo
NVAX
Novavax
7/22/2025Lower Price Target$6.99$9.00Neutral
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
7/22/2025Lower Price Target$152.14$192.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3/28/2025Upgrade$22.19$42.00Buy
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3/5/2025Lower Price Target$4.64$12.00Neutral
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2/7/2025Initiated Coverage$7.80$15.00Buy